105 related articles for article (PubMed ID: 17645577)
1. L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial.
Leboeuf R; Perron P; Carpentier AC; Verreault J; Langlois MF
Clin Endocrinol (Oxf); 2007 Dec; 67(6):839-44. PubMed ID: 17645577
[TBL] [Abstract][Full Text] [Related]
2. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism.
Siegmund W; Spieker K; Weike AI; Giessmann T; Modess C; Dabers T; Kirsch G; Sänger E; Engel G; Hamm AO; Nauck M; Meng W
Clin Endocrinol (Oxf); 2004 Jun; 60(6):750-7. PubMed ID: 15163340
[TBL] [Abstract][Full Text] [Related]
3. Timing of Hormone Withdrawal in Children Undergoing 131I Whole-Body Scans for Thyroid Cancer.
Turpin S; Lambert R; Deal C
Horm Res Paediatr; 2016; 86(6):410-415. PubMed ID: 27902975
[TBL] [Abstract][Full Text] [Related]
4. Comparison of conventional L-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing.
Marturano I; Russo M; Spadaro A; Latina A; Malandrino P; Regalbuto C
J Endocrinol Invest; 2015 Sep; 38(9):1017-22. PubMed ID: 26070652
[TBL] [Abstract][Full Text] [Related]
5. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
6. Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma.
Sánchez R; Espinosa-de-los-Monteros AL; Mendoza V; Brea E; Hernández I; Sosa E; Mercado M
Arch Med Res; 2002; 33(5):478-81. PubMed ID: 12459319
[TBL] [Abstract][Full Text] [Related]
7. Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone.
Escobar-Morreale HF; Botella-Carretero JI; Gómez-Bueno M; Galán JM; Barrios V; Sancho J
Ann Intern Med; 2005 Mar; 142(6):412-24. PubMed ID: 15767619
[TBL] [Abstract][Full Text] [Related]
8. The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients.
Celi FS; Zemskova M; Linderman JD; Babar NI; Skarulis MC; Csako G; Wesley R; Costello R; Penzak SR; Pucino F
Clin Endocrinol (Oxf); 2010 May; 72(5):709-15. PubMed ID: 20447070
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
10. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal.
Vaiano A; Claudio Traino A; Boni G; Grosso M; Lazzeri P; Colato C; Davì MV; Francia G; Lazzeri M; Mariani G; Ferdeghini M
Nucl Med Commun; 2007 Mar; 28(3):215-23. PubMed ID: 17264781
[TBL] [Abstract][Full Text] [Related]
11. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.
Clyde PW; Harari AE; Getka EJ; Shakir KM
JAMA; 2003 Dec; 290(22):2952-8. PubMed ID: 14665656
[TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine.
Celi FS; Zemskova M; Linderman JD; Smith S; Drinkard B; Sachdev V; Skarulis MC; Kozlosky M; Csako G; Costello R; Pucino F
J Clin Endocrinol Metab; 2011 Nov; 96(11):3466-74. PubMed ID: 21865366
[TBL] [Abstract][Full Text] [Related]
13. Effects of evening vs morning thyroxine ingestion on serum thyroid hormone profiles in hypothyroid patients.
Bolk N; Visser TJ; Kalsbeek A; van Domburg RT; Berghout A
Clin Endocrinol (Oxf); 2007 Jan; 66(1):43-8. PubMed ID: 17201800
[TBL] [Abstract][Full Text] [Related]
14. Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial.
Saravanan P; Simmons DJ; Greenwood R; Peters TJ; Dayan CM
J Clin Endocrinol Metab; 2005 Feb; 90(2):805-12. PubMed ID: 15585551
[TBL] [Abstract][Full Text] [Related]
15. Twenty-four hour hormone profiles of TSH, Free T3 and free T4 in hypothyroid patients on combined T3/T4 therapy.
Saravanan P; Siddique H; Simmons DJ; Greenwood R; Dayan CM
Exp Clin Endocrinol Diabetes; 2007 Apr; 115(4):261-7. PubMed ID: 17479444
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
17. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
18. [Thyroid function and thyroid autoimmunity at the late pregnancy: data from 664 pregnant women].
Guan HX; Li CY; Li YS; Fan CL; Teng Y; Ouyang YH; Cong Q; Teng WP
Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):529-32. PubMed ID: 17083836
[TBL] [Abstract][Full Text] [Related]
19. Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation.
Grigsby PW; Siegel BA; Bekker S; Clutter WE; Moley JF
J Nucl Med; 2004 Apr; 45(4):567-70. PubMed ID: 15073251
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of procollagen III peptide as a marker of tissue hyperthyroidism in long-term treated women with TSH suppressive doses of thyroxine.
Zulewski H; Siggelkow H; Walden C; Becker W; Hüfner M
Exp Clin Endocrinol Diabetes; 1999; 107(3):190-4. PubMed ID: 10376444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
